The first approved cervical cancer vaccine produced by GlaxoSmithKline in China has passed the inspection of relevant quality inspection departments in China, and has been officially listed and supplied to the whole country. The first batch of imported vaccines is 274,000, and the validity period is 20 19 1 1 month.
At present, Jiangxi and Chongqing have taken the lead in completing the bidding. The first batch of vaccines arrived yesterday and are being sent to CDC and vaccination sites in two provinces, cities and counties. Other provinces that have completed bidding access will also start issuing this week.
According to the purchasing announcements of various provinces, the bid-winning price of bivalent cervical cancer vaccine (preventive vaccine against human papillomavirus 16 and 18) is one dose from 580 yuan, and three doses * * * total 1740 yuan, which is about RMB 1000 lower than that of Hong Kong. At present, the price of this vaccine in Hong Kong is about 1200 Hong Kong dollars, equivalent to RMB. GlaxoSmithKline said that 580 yuan won the bid, but due to the cold chain management fee and vaccination service fee, the final price paid by vaccinators in different provinces will be different.
It is reported that the bivalent cervical cancer vaccine has been included in the second-class vaccine in the provinces that have completed the bidding, that is, voluntary self-funded vaccination. In addition, bivalent cervical cancer vaccine has been approved for marketing in 132 countries and regions (including Chinese mainland), and HPV vaccine has been included in national immunization programs in 70 countries around the world.
Cervical cancer is the most common gynecological malignant tumor. The high incidence age of carcinoma in situ is 30 ~ 35 years old, and the onset age of invasive carcinoma is 45 ~ 55 years old. In recent years, the incidence of cancer in situ has a trend of youthfulness. In recent decades, the extensive application of cervical cytology screening has enabled early detection and treatment of cervical cancer and precancerous lesions, and the incidence and mortality of cervical cancer have decreased significantly.